Eh, the oral polio vaccine is old, cheap, and kind of predates the rise of modern big pharma. Disease eradication is just a hard problem in general. The only human infectious disease that's been eradicated - smallpox - was a particularly easy target for various unique reasons, including the existence of a live vaccine that was incredible effective despite being so wildly different from the actual disease-causing virus that it couldn't easily cause serious disease in humans itself.
Maybe, but that kind of company probably aims its products at the First World customer.
We have eradicated pathogens before...
Two ever, one of which was a cat virus.
I personally believe that those qualities are orthogonal.
Are you saying pharma execs would prefer a working product over a profitable one?
Not the GP, but I'd say that it's easier to overprice an effective product.
Recurring revenue vs one time purchase. Not saying this is the case, but we see the obvious attraction to recurring revenue from most software companies.